by Madaline Spencer | Jul 8, 2025
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic (linvoseltamab-gcpt) for the treatment of adults with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome...
by Madaline Spencer | Jul 7, 2025
Paolo Ghia, MD, PhD, Professor of Medical Oncology at Università Vita-Salute San Raffaele in Milan, Italy, discusses results from clinical trial testing ibrutinib plus venetoclax in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)....
by Madaline Spencer | Jul 3, 2025
Krish Patel, MD, Medical Oncologist at Sarah Cannon Research Institute, discusses first results from a study evaluating CAR-T cell therapy for large B cell lymphoma (LBCL). LBCL is a form of non-Hodgkin lymphoma. Lymphomas occur when cells of the immune...
by Madaline Spencer | Jul 2, 2025
Andrew T. Kuykendall, MD, Associate Member in the Department of Hematology at Moffitt Cancer Center, discusses results from the VERIFY clinical trial in polycythemia vera (PV). PV is a rare condition characterized by an increased number of red blood...
by Madaline Spencer | Jul 1, 2025
Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses results from the CEPHEUS clinical trial in multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by a serum...
